Description
INVOKANA® 300 MG TABLETS (30’s)
Overview:
INVOKANA® (canagliflozin) is an oral medication used to manage blood sugar levels in adults with type 2 diabetes. It belongs to the class of drugs known as sodium-glucose co-transporter 2 (SGLT2) inhibitors. By inhibiting the SGLT2 protein in the kidneys, INVOKANA® reduces glucose reabsorption, leading to increased glucose excretion in urine and thereby lowering blood sugar levels.
Dosage and Administration:
The typical starting dose is 100 mg once daily, taken before the first meal of the day. If well-tolerated, the dose may be increased to 200 mg daily, and in some cases, up to 300 mg daily for additional glycemic control. The maximum recommended dose is 300 mg daily, particularly for patients with an estimated glomerular filtration rate (eGFR) of 60 mL/min/1.73 m² or higher. For those with eGFR between 30 and 60 mL/min/1.73 m², the maximum recommended dose is 200 mg daily. Initiation of INVOKANA® is not recommended for patients with eGFR below 30 mL/min/1.73 m².
Uses:
- Type 2 Diabetes Management: INVOKANA® helps lower blood sugar levels when used alongside diet and exercise.
- Cardiovascular Risk Reduction: It reduces the risk of heart attack, stroke, and cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.
- Kidney Protection: INVOKANA® lowers the risk of end-stage kidney disease, worsening kidney function, and hospitalization for heart failure in patients with type 2 diabetes and diabetic kidney disease with protein in the urine.
Side Effects:
Common side effects include:
- Genital yeast infections
- Increased urination
- Thirst
- Constipation
- Nausea
Serious side effects may include:
- Dehydration leading to dizziness or fainting
- Low blood pressure
- Kidney problems
- Increased risk of bone fractures
- Ketoacidosis (a serious condition where the body produces high levels of blood acids called ketones)
Patients should contact their healthcare provider if they experience symptoms such as nausea, vomiting, abdominal pain, or difficulty breathing.
Precautions:
- Not for Type 1 Diabetes: INVOKANA® is not intended for use in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.
- Kidney Function: Regular monitoring of kidney function is recommended, as the medication is not suitable for those with severe kidney impairment.
- Pregnancy and Breastfeeding: INVOKANA® should be avoided during pregnancy and breastfeeding unless the potential benefits justify the potential risks to the fetus or infant.
Storage:
Store at room temperature, away from moisture and heat. Keep out of reach of children.
Conclusion:
INVOKANA® 300 MG tablets offer an effective option for managing type 2 diabetes, with additional benefits for heart and kidney health. It is essential to use this medication under the guidance of a healthcare professional, with regular monitoring to ensure safety and efficacy.
Reviews
There are no reviews yet.